Sakiris Spiro Kevin 4
4 · INTELLIGENT BIO SOLUTIONS INC. · Filed Mar 21, 2024
Insider Transaction Report
Form 4
Sakiris Spiro Kevin
Chief Financial Officer
Transactions
- Exercise of In-Money
Common Stock
2024-03-20+9,394→ 19,180 total(indirect: Held by Anest Holdings Pty Ltd) - Exercise of In-Money
Common Stock Warrants (Series F)
2024-03-20−9,394→ 0 total(indirect: Held by Anest Holdings Pty Ltd)Exp: 2025-04-04→ Common Stock (9,394 underlying)
Holdings
- 314
Common Stock
Footnotes (4)
- [F1]The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split").
- [F2]The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore.
- [F3]The Series F Warrants became exercisable on November 17, 2023, the date the Issuer's stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), the issuance of the shares underlying the Series F Warrants.
- [F4]These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.